Mabspace Biosciences Co. Ltd., of Suzhou, China, said it completed a $15 million series A round to advance its pipeline of therapeutic antibody programs into clinical studies, and to enable expanded discovery of antibodies aimed at various components of tumor microenvironment to enhance responses of tumors that may be less likely to respond to T-cell checkpoint monotherapy.